Cargando…

FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib

Fibroblast growth factor receptor (FGFR) family includes four highly conserved receptor tyrosine kinases. Particularly, FGFR2 has been identified as a potential target for tyrosine kinase inhibitor (TKI) treatment. Except for immunohistochemistry and fluorescence in situ hybridization, next-generati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ying, Xihui, Tu, Jianfei, Wang, Wenxian, Li, Xingliang, Xu, Chunwei, Ji, Jiansong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842751/ https://www.ncbi.nlm.nih.gov/pubmed/31807010 http://dx.doi.org/10.2147/OTT.S218796

Ejemplares similares

FGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib
por: Hong, Chen, et al.
Publicado: (2022)

FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures
por: Sridharan, Vishwajith, et al.
Publicado: (2022)

Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas
por: Pu, Xiaohong, et al.
Publicado: (2023)

Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma
por: Kongpetch, Sarinya, et al.
Publicado: (2020)

Oncogenic FGFR3 gene fusions in bladder cancer
por: Williams, Sarah V., et al.
Publicado: (2013)

Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing
por: Neumann, Olaf, et al.
Publicado: (2022)

Generation of An Endogenous FGFR2–BICC1 Gene Fusion/58 Megabase Inversion Using Single-Plasmid CRISPR/Cas9 Editing in Biliary Cells
por: Reicher, Andreas, et al.
Publicado: (2020)

Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma
por: Tsujie, Masanori, et al.
Publicado: (2021)

FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium
por: Best, Sarah A., et al.
Publicado: (2018)

Oncogenic FGFR Fusions Produce Centrosome and Cilia Defects by Ectopic Signaling
por: Nita, Alexandru, et al.
Publicado: (2021)

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
por: Mazzaferro, Vincenzo, et al.
Publicado: (2018)

Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements
por: Walden, Daniel, et al.
Publicado: (2022)

Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements
por: White, Kathryn, et al.
Publicado: (2023)

Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing
por: Hyung, Sujin, et al.
Publicado: (2022)

FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2020)

Erratum to: Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma
por: Tsujie, Masanori, et al.
Publicado: (2021)

Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
por: Wu, Tianyu, et al.
Publicado: (2021)

Oncogenic fusion protein FGFR2-PPHLN1: Requirements for biological activation, and efficacy of inhibitors
por: Li, Fangda, et al.
Publicado: (2020)

Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies
por: Lidsky, Michael E., et al.
Publicado: (2022)

Specific recognition of an FGFR2 fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma
por: White, Bradley Sinclair, et al.
Publicado: (2023)

Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma
por: Bitzer, Michael, et al.
Publicado: (2021)

FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice
por: Angerilli, Valentina, et al.
Publicado: (2023)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

Growth charts in FGFR2- and FGFR3-related faciocraniosynostoses
por: Ea, Caroline, et al.
Publicado: (2022)

Targeting the FGFR signaling pathway in cholangiocarcinoma: promise or delusion?
por: Wang, Jing, et al.
Publicado: (2020)

FGFR inhibitors in cholangiocarcinoma: what’s now and what’s next?
por: Saborowski, Anna, et al.
Publicado: (2020)

Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma
por: Lamarca, A., et al.
Publicado: (2023)

Novel mutation detection of fibroblast growth factor receptor 1 (FGFR1) gene, FGFR2IIIa, FGFR2IIIb, FGFR2IIIc, FGFR3, FGFR4 gene for craniosynostosis: A prospective study in Asian Indian patient
por: Barik, Mayadhar, et al.
Publicado: (2015)

Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas
por: Granberg, Kirsi J, et al.
Publicado: (2017)

FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes
por: Furugaki, Koh, et al.
Publicado: (2023)

Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses' Health Study
por: Nan, Hongmei, et al.
Publicado: (2009)

Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy
por: Krook, Melanie A., et al.
Publicado: (2019)

Identification and In-Depth Analysis of the Novel FGFR2-NDC80 Fusion in a Cholangiocarcinoma Patient: Implication for Therapy
por: Scheiter, Alexander, et al.
Publicado: (2021)

Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test
por: Ishido, Shun, et al.
Publicado: (2023)

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
por: Zingg, Daniel, et al.
Publicado: (2022)

Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas
por: Pu, Xiaohong, et al.
Publicado: (2021)

Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis
por: Zhang, Jinglin, et al.
Publicado: (2019)

Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
por: Rizzo, Alessandro
Publicado: (2021)

Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants
por: Lin, Qianmeng, et al.
Publicado: (2022)

FGFR2 genetic variants in women with breast cancer
por: Dix-Peek, Thérèse, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h5kbvt9tgvibp38g2l4j01qmv6